HYL — Hyloris Pharmaceuticals SA Share News
0.000.00%
Last trade - 00:00- €108.08m
- €100.44m
- €7.21m
Brief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
Brief: Hyloris Announces Partnership With Rosemont Pharmaceuticals For Atomoxetine Oral Solution In The U.S.
Brief: Hyloris Announces Positive Study Results For Dofetilide IV
Brief: Hyloris Pharmaceuticals SA Says HY 2024 Revenues (Royalties And Milestones) Increased To EUR 4,2 Million
Brief: Euronext Announces Quarterly Review Of BEL Family Indices
Brief: Hyloris Signs Exclusive Licensing, Distribution Agreement For Maxigesic IV In Brazil
French and Benelux stocks-Factors to watch
Belgian finance regulator issues warning about Hyloris Pharmaceuticals
Brief: Belgium's FSMA regulator issues warning over information from Hyloris Pharmaceuticals
Brief: Hyloris Pharmaceuticals Sees Sales Growth In 2024
Brief: Hyloris Pharmaceuticals: Revision Of 2022, H1 2023 Financial Statements Following Correction Of Non-Cash Error
Brief: Hyloris Pharmaceuticals FY Net Income EUR -15.762 Million
Brief: Hyloris Announces Launch Of Maxigesic® Iv In U.S. And Approval In Canada
Brief: Hyloris Says Enrolls First Patient In Phase 3 Clinical Trial For Proprietary Mouth Rinse To Control Incidences Of Bleeding Related To Dental Procedures
Brief: Hyloris: Positive Results From Phase 2 Trial In Patients With VVC
Develop New Product Candidate For Vulvar Lichen Sclerosus
Brief: Pleco Therapeutics Receives FDA Orphan Drug Designation
Brief: Hyloris Pharmaceuticals Broadens Pipeline With New Product Candidate In Burning Mouth Syndrome
Brief: Hyloris Announces US FDA Approval For Podofilox Gel